mRNA, widely known from the COVID-19 vaccine, is not actually a “therapeutic agent,” but a technology that delivers the blueprint for functional proteins into the body so that induces therapeutic effects. Recently, its application has expanded to cancer and genetic disease treatments, but mRNA therapeutics have caused serious side effects such as pulmonary embolism, stroke, thrombosis, and autoimmune diseases because proteins are excessively produced all at once immediately after administration. Although technology to control the endogenous protein factory has been continuously needed, there had been no suitable solution.

A new generation of targeted treatments and gentler chemotherapy options for older adults with a new diagnosis of acute myeloid leukemia (AML) is driving better survival and cure rates.

A new study published in the journal Scientific Reports shows that Claudin-4, a protein that increases in ovarian cancer, may be the culprit behind the cancer’s resistance, helping tumors both survive and hide from the body’s immune system.

Cells stop dividing when telomeres become too short to protect chromosomes, a process known as replicative senescence. But what drives it, and why cells senesce far earlier under high-oxygen conditions than under low-oxygen conditions, was not fully understood. The study shows that replicative senescence is enforced solely by the ATM kinase, and that high oxygen generates a hyperactive form of ATM that forces cells to arrest earlier. In low oxygen states, ATM’s less active form tolerates shorter telomeres. Because most tumors experience low oxygen levels, their reduced ATM response could allow cancer cells to tolerate very short telomeres, raising the possibility that reactivating ATM could stop tumor growth.

BUFFALO, NY — December 1, 2025 — A new research paper featured on the cover of Volume 17, Issue 11 of Aging-US was published on October 30, 2025, titled “SAMP-Score: a morphology-based machine learning classification method for screening pro-senescence compounds in p16 positive cancer cells.”

In a recent pioneering study, researchers at Insilico Medicine ("Insilico"), a generative artificial intelligence (AI)-driven clinical-stage biotechnology company, harnessed its AI-driven generative chemistry platform, Chemistry42, to design a novel, first-in-class PROTAC targeting PKMYT1, D16-M1P2, which employs a dual mechanism of action—inducing PKMYT1 degradation while directly inhibiting its kinase activity. This innovative strategy holds promise for overcoming limitations of existing inhibitors, such as poor selectivity and acquired resistance, and to effectively target both the catalytic and non-catalytic functions of PKMYT1. As a result, the PROTAC demonstrates the potential for a more selective, potent, and durable therapeutic effect.

An international research team led by RMIT University have created tiny particles, known as nanodots, made from a metallic compound that can kill cancer cells while leaving healthy cells largely unharmed.

While this work is still at the cell-culture stage – it hasn’t been tested in animals or people – it points to a new strategy for designing cancer treatments that exploit cancer’s own weaknesses.

- Follicular Lymphoma (FL) is one of the most common types of blood cancer, accounting for 20–25% of all non-Hodgkin lymphomas (NHL). Each year, approximately 15,000 new cases are diagnosed in the United States and 2,000 in Spain.

- Despite the disease’s biological diversity, most patients still receive similar treatment approaches, and relapse remains common.

- A new global alliance, led by Dr. Ari Melnick, Director of the Josep Carreras Leukaemia Research Institute, will unite leading research teams from the United States and Spain to develop innovative diagnostic tools and treatment strategies for patients with FL.

- This international initiative is supported by Blood Cancer United®—formerly The Leukemia & Lymphoma Society—and the Institute for Follicular Lymphoma Innovation (IFLI) through the Research Accelerator for Follicular Lymphoma (RAFL) Synergistic Team Award (STA).

A study of data from seven outpatient facilities in the New York region found that 20-24% of all the breast cancers diagnosed during an 11-year period were found in women age 18 to 49, according to research being presented today at the annual meeting of the Radiological Society of North America (RSNA).